NCT01984788View on ClinicalTrials.gov

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Hereditary Angioedema
Interventions
DRUG

BCX4161

DRUG

Placebo

Trial Locations (6)

Unknown

Dr Marcus Maurer, Berlin

Dr Emel Aygoren-Pursun, Frankfurt

Dr Petra Staubach, Mainz

Dr Inmaculada Martinez-Saguer, Mörfelden-Walldorf

Dr Murat Bas, München

Dr Hilary Longhurst, London

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT01984788 - Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE | Biotech Hunter | Biotech Hunter